

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Participates in the 14th Redefining Early Stage Investments Conference

Wilmington, DE – September 20, 2017 – CureDM announces plans to participate in the 14th Redefining Early Stage Investing (RESI) Conference in Boston, Massachusetts on September 26. The conference is being held at the Boston Marriott Copley Place in conjunction with Johnson & Johnson.

CEO, Loraine Upham states, “Using the Premier Partnering Plus platform, we will be sharing our strategic plans with investors and strategic partners as well as networking with potential service providers from all over the world.”

CureDM is actively engaged in fundraising, clinical development planning and partnering to bring forth a novel treatment approach to diabetes with their lead compound, HIP2B. HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications are being pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX